|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 22, 2014 ) Dallas, TX -- The main drivers of growth in graft versus host disease over the 2013-2018 forecast period include the increasing numbers of allogeneic hematopoietic stem cell transplants and the increasing use of biologic off-label and marketed therapies in the 6MM.
Sanofi is a key player in the GVHD market with Thymoglobuline and Lemtrada by infiltrating prophylaxis, aGVHD and cGVHD. J&Js Remicade, has gained a significant patent share of the aGVHD patient group, as it is one of the few drugs that are efficient in GVHD with GI involvement. Gaining more and more ground in the treatment management of cGVHD is Roches Rituxan that GlobalData estimates will be one of the bestselling biologics in GVHD in the US by 2018.
The GVHD market was valued at $297.0m across the 6MM in 2013, and is expected to increase to $409.0m in 2018, at a Compound Annual Growth Rate (CAGR) of 6.61%.
Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=206742 . (This is a premium report priced at US $5995 for a single user License.)
Despite the vast array of available off-label therapies for the treatment and/or prevention of GVHD, very few of these therapies have been tested in large randomised trials. This results in vague treatment recommendations and many patients being enrolled in institutional clinical trials. The only available standard of care is intravenous methylprednisolone that fails to produce a complete response in more than 50% of treated patients. Steroid-refractory subgroups face low prognosis with deteriorating quality of life. Second and third life treatments can vary from country to country but also between different medical institutions in the same country.
Key Questions Answered
How will the GVHD market landscape change within the 2013-2018 forecast period in the 6MM?
What are the most promising late-pipeline drugs in GVHD?
How do the clinical and commercial attributes of late-stage pipeline therapies compare to one another and against existing treatment options?
What are the unmet needs in GVHD treatment management?
What needs to change in the GVHD R&D and treatment guidelines settings?
Key Findings
High uptake of off-label biologics (Rituxan, Lemtrada, Remicade and Thymoglobuline)
No national guidelines are in place
GVHD remains a field of highly unattained unmet need
No consensus over clinical trial endpoints
Regulatory T cells (Tregs) are the focus of the early stage pipeline
Huge opportunity exists in the chronic patient segment of GVHD
Institutionally funded studies are the core of GVHD treatment management
Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=206742 . (This is a premium report priced at US $5995 for a single user License.)
List of Companies
Sanofi, Novartis, Neovii, J&J, Merck, Amgen, Eisai, Novartis, BMS, Astellas Pharma, Genzyme, Roche, Pfizer, Millenium Pharmaceuticals, Warner Lambert, Hospira, Jazz Pharmaceuticals, Adienne Pharma, Dr Falk Pharma, Mesoblast, Osiris, Athersys, Therakos, Soligenix, Janssen Cilag.
Scope
Overview of GVHD, including epidemiology, etiology, pathophysiology, symptoms and current treatment options
Annualized GVHD therapeutics market revenue, annual cost of therapies and forecasts for five years to 2018.
Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the GVHD therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including TNF blockers, CD25a blockers, GVHD specific therapies etc.
Analysis of the current and future market competition in the US and five major EU GVHD therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies. Insightful review of the key industry drivers, restraints and challenges.
Key markets covered are US, France, Germany, Italy, Spain, UK
Reasons To Buy
Identify the unmet needs and remaining opportunities in the GVHD therapeutics market.
Develop business strategies by understanding the trends shaping and driving the US and five major EU GVHD therapeutics market.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Assess the clinical and commercial viability of promising pipeline products.
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various emerging therapies.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Drive revenues by understanding the key trends, innovative products and technologies, market and segments likely to impact the US and five major EU GVHD therapeutics market in future
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
